Download in electronic PDF format for $25



Search the Complete Journal Archives

Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules

Author(s):  Fortner Jeff,Salton Jason,Carlson Christie,Wheeler Rich,Cote Brianna,Rao Deepa

Issue:  Sep/Oct 2015 - Volume 19, Number 5
View All Articles in Issue

Abstract:  The purpose of this research was to collect, analyze, and compare stability data for levothyroxine (T4) powder in the anhydrous and pentahydrate form when prepared as an aliquot and in capsules. Two different compounding pharmacies, Central Iowa Compounding and Gateway Medical Pharmacy, used different forms of T4 and aliquot formulations, which were studied to determine the beyond-use date at ±5% or ±10% of labeled strength. T4 was extracted from aliquot and capsule formulations and assessed using reverse-phase highperformance liquid chromatography validated to differentiate between the degraded and original forms of T4. The results indicate that T4 1:100 aliquot formulation prepared with silica gel or Avicel as filler are stable for 120 days at ±10% labeled potency, but at ±5% labeled potency, the silica gel and Avicel aliquot formulations are stable for 45 and 30 days, respectively. The silica gel capsules prepared from fresh aliquot were stable for 120 days at ±10% labeled potency and 90 days at ±5% labeled potency, while the Avicel capsules prepared from fresh aliquot were stable for 180 days at both ±10% and ±5% labeled potency. Avicel capsules prepared from old aliquot (120 days) and fresh aliquot (1 day) were also compared for stability. The old aliquot Avicel capsules were stable for 14 days at ±5% labeled potency and 150 days at ±10% labeled potency, while new aliquot Avicel capsules were stable for 180 days at both ±10% and ±5% labeled potency. Based on our data, there can be significant variation in the beyond-use dates assigned to T4 capsules based on the diluents used for aliquots, the final capsule formulations, and the potency standards applied. These results also indicate that pharmacists must exercise caution when using older aliquots and may have to assign shorter beyond-use dates.

Related Keywords: Jeff Fortner, PharmD, Jason Salton, PharmD, Christie Carlson, RPh, Rich Wheeler, RPh, Brianna Cote, Deepa Rao, PhD, levothyroxine, hypothyroidism, thyroid T4 replacement hormone, anhydrous, pentahydrate, aliquots, capsules, stability, potency standards, storage temperature

Related Categories: EXCIPIENTS, FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Fortner Jeff, Salton Jason, Carlson Christie, Wheeler Rich, Cote Brianna, Rao Deepa Sep/Oct 2015 414-419 Buy
Assessing the Use of Food Coloring as an Appropriate Visual Guide for Homogenously Mixed Capsule Powders in Extemporaneous Compounding Hoffmann Brittany, Carlson Christie, Rao Deepa A Jul/Aug 2014 341-344 Buy
Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Snyder Scott, Listecki Robert E Sep/Oct 2012 376-380 Buy
Hypothyroidism: Optimizing Therapy with Slow-Release Compounded Thyroid Replacement Milner Martin Jul/Aug 2005 268-273 Buy
The Science Behind Hormone Replacement Therapy, Part 1 Wepfer Scott T Nov/Dec 2001 462 Buy
Thyroid Potency Calculations Stack Bob Jul/Aug 2010 306-309 Buy
Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism Paoletti Jim Nov/Dec 2008 488-497 Buy
Levothyroxine Sodium 100-mcg Capsules Allen Loyd V Jr Nov/Dec 2013 505 Buy
Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3) Bakhteyar Hamid, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N Sep/Oct 2017 418-425 Buy
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh Allen Loyd V Jr Nov/Dec 2003 449-450 Buy